Cardiac allograft vasculopathy medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
===Pharmacologic Management=== | |||
===Nonpharmacologic Interventions=== | |||
* Retransplantation | |||
* [[Percutaneous coronary interventions | |||
* Coronary artery bypass grafting | |||
* Transmyocardial laser revascularization | |||
* Heparin induced/mediated extracorporeal LDL plasmapheresis (HELP) | |||
==References== | ==References== |
Revision as of 20:14, 7 December 2014
Cardiac allograft vasculopathy Microchapters |
Differentiating Cardiac allograft vasculopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cardiac allograft vasculopathy medical therapy On the Web |
American Roentgen Ray Society Images of Cardiac allograft vasculopathy medical therapy |
Directions to Hospitals Treating Cardiac allograft vasculopathy |
Risk calculators and risk factors for Cardiac allograft vasculopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Medical Therapy
Pharmacologic Management
Nonpharmacologic Interventions
- Retransplantation
- [[Percutaneous coronary interventions
- Coronary artery bypass grafting
- Transmyocardial laser revascularization
- Heparin induced/mediated extracorporeal LDL plasmapheresis (HELP)